105 related articles for article (PubMed ID: 28280996)
21. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
22. Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.
Chang WJ; Ko YH; Kim SJ; Kim WS
Leuk Lymphoma; 2014 Sep; 55(9):2196-8. PubMed ID: 24308435
[No Abstract] [Full Text] [Related]
23. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
[TBL] [Abstract][Full Text] [Related]
24. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
25. [Long-term remission of a nasal NK/T-cell lymphoma patient with massive involvement of the orbita and liver dysfunction].
Monma F; Ueno S; Yamaguchi M; Tawara I; Miyazaki K; Nishii K; Nakase K; Katayama N
Rinsho Ketsueki; 2009 Jan; 50(1):44-8. PubMed ID: 19225229
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.
Liang JH; Wang L; Peter Gale R; Wu W; Xia Y; Fan L; Li JY; Xu W
Blood Cancer J; 2017 Sep; 7(9):e608. PubMed ID: 29016569
[No Abstract] [Full Text] [Related]
28. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
29. Nasal extranodal peripheral NK/T-cell lymphoma treated by the protocol NK/T-cell high-dose-methotrexate L-asparaginase dexamethasone.
Bekadja MA; Benredouane H; Audouin J; Mansouri D; Mehadji H; Brahimi M; Arabi A; Osmani S; Entasoltane B
Hematol Oncol Stem Cell Ther; 2011; 4(1):49-50. PubMed ID: 21460609
[No Abstract] [Full Text] [Related]
30. Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation.
McEachron TA; Kirov I; Wungwattana M; Cortes D; Zabokrtsky KB; Sassoon A; Craig D; Carpten JD; Sender LS
Pediatr Blood Cancer; 2016 Apr; 63(4):727-30. PubMed ID: 26727971
[TBL] [Abstract][Full Text] [Related]
31. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of secondary NK/T-cell lymphoma of the testis.
Kobayashi T; Hangaishi A; Yamamoto G; Shinohara A; Morikawa T; Takazawa Y; Ota S; Imai Y; Nakamura F; Kurokawa M
Ann Hematol; 2013 Jul; 92(7):997-8. PubMed ID: 23271214
[No Abstract] [Full Text] [Related]
33. A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.
Yang J; Shi Y; He X; Dong M; Zhang C; Liu P; Zhou S; Qin Y; Gui L; Yang S; Sun Y
Leuk Lymphoma; 2015 Jul; 56(7):2218-21. PubMed ID: 25563558
[No Abstract] [Full Text] [Related]
34. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
Xiong X; Cai Z; Yang J; Shu X
J Cancer Res Ther; 2015; 11(3):665. PubMed ID: 26458696
[TBL] [Abstract][Full Text] [Related]
36. [Primary colonic extranasal NK/T-cell lymphoma: about a case].
Fares S; Lamchahab M; Aniba M; Lembarki G; Mousalli N; Regragui M; Karkouri M; Quessar A
Pan Afr Med J; 2017; 26():112. PubMed ID: 28533835
[TBL] [Abstract][Full Text] [Related]
37. Nasal Type Extranodal Natural Killer/T (NK/T) Cell Lymphoma Presenting as Periorbital Cellulitis: A Case Report.
Al Shawabkeh MA; Al Sulaiti M; Al Sa'ey H; Ganesan S
Am J Case Rep; 2016 Dec; 17():934-938. PubMed ID: 27932776
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of localized nasal NK/T-cell lymphoma].
Yamaguchi M
Rinsho Ketsueki; 2008 Aug; 49(8):553-8. PubMed ID: 18800601
[No Abstract] [Full Text] [Related]
40. Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients.
Uemoto S; Ozawa K; Kaido T; Mori A; Fujimoto Y
Clin Exp Immunol; 2016 Apr; 184(1):126-36. PubMed ID: 26560892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
